BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 13, 2004
View Archived Issues
Threshold's Oncology Products Emerge Through $41M Series B
Stepping into the biotech spotlight, cancer drug developer Threshold Pharmaceuticals Inc. raised $41 million in a second round of financing that attracted new and existing investors. (BioWorld Today)
Read More
Regeneron CEO: Beware 'Fibs' From Prospective Dealmakers
Read More
BioPort Gets Anthrax Vaccine Contract Worth Up To $245M
Read More
Concurrent Raises $15M, Partners With Intel On 'Machine Learning'
Read More
Inhibitex Series E Raises $20M To Advance Veronate, Aurexis
Read More
Other News To Note
Read More